对AECOPD患者使用布地奈德、氨溴索及复方异丙托溴铵进行雾化吸入治疗的效果探讨

The effects of inhalation of budesonide, ambroxol and ipratropium on AECOPD patients were discussed

目的:探讨对AECOPD(慢性阻塞性肺疾病急性加重期)患者使用布地奈德、氨溴索及复方异丙托溴铵进行雾化吸入治疗的效果。方法:将2015年1月至2017年3月期间西南医科大学附属中医医院收治的69例AECOPD患者作为研究对象。将这69例患者按照入院的顺序分为对照组和观察组,对照组有34例患者,观察组有35例患者。对对照组患者使用布地奈德进行雾化吸入治疗。对观察组患者使用布地奈德、氨溴索及复方异丙托溴铵进行雾化吸入治疗。然后,比较两组患者的临床疗效、不良反应的发生率、呼吸困难的评分、动脉氧分压(PaO_2)、二氧化碳分压(PaCO_2)。结果 :接受治疗后,观察组患者治疗的总有效率及PaO_2均高于对照组患者,其呼吸困难的评分及PaCO_2均低于对照组患者(P <0.05)。结论 :对AECOPD患者使用布地奈德、氨溴索及复方异丙托溴铵进行雾化吸入治疗的效果显著。

objective： to investigate the efficacy of inhalation of budesonide, ambroxol and ipratropium in the treatment of patients with AECOPD（acute exacerbation of chronic obstructive pulmonary disease）. Methods： 69 patients with AECOPD admitted to the hospital of traditional Chinese medicine of southwest medical university from January 2015 to March 2017 were studied. The 69 patients were divided into the control group and the observation group according to the sequence of admission. There were 34 patients in the control group and 35 patients in the observation group. The control group was treated with budesonide inhalation. The patients in the observation group were treated by inhalation of budesonide, ambroxol and ipratropium bromide. Then, clinical efficacy, incidence of adverse reactions, dyspnea score, arterial oxygen partial pressure（PaO2） and carbon dioxide partial pressure（PaCO2） were compared between the two groups. Results： after treatment, the total treatment efficiency and PaO2 in the observation group were higher than those in the control group, and the score of dyspnea and PaCO2 were lower than those in the control group（P 0.05）. Conclusion： the use of budesonide, ambroxol and ipratropium bromide in the treatment of AECOPD patients with atomization inhalation is effective.